MX2019002289A - Composicion inyectable para reduccion de grasa localizada, sin dolor, edema ni efectos secundarios, y metodo para preparar la misma. - Google Patents
Composicion inyectable para reduccion de grasa localizada, sin dolor, edema ni efectos secundarios, y metodo para preparar la misma.Info
- Publication number
- MX2019002289A MX2019002289A MX2019002289A MX2019002289A MX2019002289A MX 2019002289 A MX2019002289 A MX 2019002289A MX 2019002289 A MX2019002289 A MX 2019002289A MX 2019002289 A MX2019002289 A MX 2019002289A MX 2019002289 A MX2019002289 A MX 2019002289A
- Authority
- MX
- Mexico
- Prior art keywords
- pain
- side effects
- fat reduction
- edema
- composition
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title abstract 6
- 230000036407 pain Effects 0.000 title abstract 5
- 206010030113 Oedema Diseases 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 4
- 239000007972 injectable composition Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000002347 injection Methods 0.000 abstract 4
- 239000007924 injection Substances 0.000 abstract 4
- 210000001789 adipocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 3
- 206010002091 Anaesthesia Diseases 0.000 abstract 2
- 206010006784 Burning sensation Diseases 0.000 abstract 2
- 206010015150 Erythema Diseases 0.000 abstract 2
- 206010054107 Nodule Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000037005 anaesthesia Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 231100000321 erythema Toxicity 0.000 abstract 2
- 210000002950 fibroblast Anatomy 0.000 abstract 2
- 230000007803 itching Effects 0.000 abstract 2
- 210000000663 muscle cell Anatomy 0.000 abstract 2
- 230000017074 necrotic cell death Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000035807 sensation Effects 0.000 abstract 2
- 230000008961 swelling Effects 0.000 abstract 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 108010007979 Glycocholic Acid Proteins 0.000 abstract 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 abstract 1
- 229940099347 glycocholic acid Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004130 lipolysis Effects 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con una composición para reducir grasa localizada sin dolor, edema ni efectos secundarios, y con un método para preparar la misma. Más específicamente, la presente invención se relaciona con una composición que comprende ácido glicocólico (o una sal del mismo) o ácido taurocólico (o una sal del mismo) y fosfatidilcolina (PPC) en una proporción de mezcla particular para reducir grasa localizada sin efectos secundarios tales como dolor, edema, necrosis de células musculares, fibroblastos y células del endotelio vascular distintas de los adipocitos, anestesia de los sitios de administración, hinchamiento extenso, eritema, endurecimiento, parestesia, nódulo, prurito, sensación de ardor, daño nervioso, y disfagia, y con un método para preparar la misma. Se conoce que la preparación inyectable simple de DCA o preparación inyectable PPC en la cual se mezcla DCA como un agente solubilizante, que son las preparaciones inyectables convencionales para reducir grasa localizada, están acompañadas de dichos efectos secundarios tales como dolor, anestesia, hinchamiento extenso, edema localizado, eritema, endurecimiento, parestesia, nódulo, prurito, sensación de ardor, disfagia y lo similar debido a necrosis de células causada inevitablemente por la lisis de no sólo adipocitos sino también fibroblastos, células del endotelio vascular y células de músculo esquelético. De ese modo los pacientes se han estado quejando de dolor, malestar y ansiedad, con bajo cumplimiento. Por otra parte, la composición inyectable para reducir grasa localizada de acuerdo con la presente invención es una formulación segura y estable, realiza la lisis selectiva de adipocitos y tiene un excelente efecto en la inducción de apoptosis de adipocitos, de modo que es una excelente composición que mejora el cumplimiento y calidad de vida del paciente sin los efectos secundarios mencionados anteriormente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170051868 | 2017-04-21 | ||
| KR20170146264 | 2017-11-03 | ||
| PCT/KR2018/004642 WO2018194427A1 (ko) | 2017-04-21 | 2018-04-20 | 통증과 부종 그리고 부작용이 없는 국소지방 감소용 주사제 조성물 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002289A true MX2019002289A (es) | 2019-09-26 |
Family
ID=63229610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002289A MX2019002289A (es) | 2017-04-21 | 2018-04-20 | Composicion inyectable para reduccion de grasa localizada, sin dolor, edema ni efectos secundarios, y metodo para preparar la misma. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11298314B2 (es) |
| EP (1) | EP3479827B1 (es) |
| JP (1) | JP7034497B2 (es) |
| KR (1) | KR101887586B1 (es) |
| CN (1) | CN109862897B (es) |
| AU (1) | AU2018256263B2 (es) |
| BR (1) | BR112019008065A2 (es) |
| CA (1) | CA3031678C (es) |
| CO (1) | CO2019004317A2 (es) |
| ES (1) | ES2949946T3 (es) |
| IL (1) | IL266873B2 (es) |
| MX (1) | MX2019002289A (es) |
| RU (1) | RU2736974C1 (es) |
| WO (1) | WO2018194427A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2736974C1 (ru) | 2017-04-21 | 2020-11-23 | Ами Фарм Ко., Лтд. | Инъецируемая композиция для уменьшения локализованного жира без болевого синдрома, отёка и побочных эффектов и способ ее получения |
| KR102513115B1 (ko) | 2020-12-18 | 2023-03-22 | 주식회사 레시텍 | 리토콜릭산을 포함하는 국소지방 감소용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6663885B1 (en) * | 1993-03-15 | 2003-12-16 | A. Natterman & Cie Gmbh | Aqueous liposome system and a method for the preparation of such a liposome system |
| US20050089555A1 (en) * | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
| DE10349979B4 (de) * | 2003-10-24 | 2006-05-18 | Sanofi-Aventis Deutschland Gmbh | Medikamentöse gezielte lokale Lipolyse |
| US20050143347A1 (en) | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
| CA2550647A1 (en) * | 2003-12-22 | 2005-07-14 | Aventis Pharmaceuticals Inc. | Injectable phosphatidylcholine preparations |
| DE10361067A1 (de) * | 2003-12-22 | 2005-07-14 | Aventis Pharma Deutschland Gmbh | Medikamentöse Lipolyse von Fettansammlungen |
| ES2660172T3 (es) | 2004-05-19 | 2018-03-21 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Composición inyectable que comprende desoxicolato de sodio |
| US7754230B2 (en) | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| US20090221528A1 (en) | 2004-06-28 | 2009-09-03 | Teresa Ann Denney | Therapeutic micro nutrient composition for lipolysis and sclerosis |
| RS53402B (en) * | 2007-03-22 | 2014-10-31 | Genentech, Inc. | APPLICATION OF APOPTOTIC ANTI-IGE ANTIBODIES FOR MEMBRANE IGE |
| CN101152189B (zh) | 2007-10-12 | 2010-11-24 | 西藏海思科药业集团有限公司 | 多烯磷脂酰胆碱注射液及其制备方法 |
| US20140113883A1 (en) | 2008-12-16 | 2014-04-24 | James Robert DeLuze | Therapeutic micro nutrient composition for lipolysis and sclerosis |
| KR101173652B1 (ko) * | 2010-05-19 | 2012-08-13 | 박은희 | Ｐｐｃ 성분이 포함된 지방 분해 액상 조성물 제조 방법 |
| KR101545706B1 (ko) | 2013-05-10 | 2015-08-26 | 주식회사 아미팜 | 포스파티딜콜린을 포함하는 지방 분해용 조성물 및 이의 제조방법 |
| CN114272251A (zh) * | 2014-06-27 | 2022-04-05 | 玫帝托克斯股份有限公司 | 用于减少脂肪的胆酸类与盐类的制剂及用途 |
| RU2736974C1 (ru) | 2017-04-21 | 2020-11-23 | Ами Фарм Ко., Лтд. | Инъецируемая композиция для уменьшения локализованного жира без болевого синдрома, отёка и побочных эффектов и способ ее получения |
-
2018
- 2018-04-20 RU RU2019112583A patent/RU2736974C1/ru active
- 2018-04-20 MX MX2019002289A patent/MX2019002289A/es unknown
- 2018-04-20 KR KR1020180046228A patent/KR101887586B1/ko active IP Right Grant
- 2018-04-20 BR BR112019008065A patent/BR112019008065A2/pt active Search and Examination
- 2018-04-20 JP JP2019547440A patent/JP7034497B2/ja active Active
- 2018-04-20 AU AU2018256263A patent/AU2018256263B2/en active Active
- 2018-04-20 IL IL266873A patent/IL266873B2/en unknown
- 2018-04-20 CN CN201880002788.6A patent/CN109862897B/zh active Active
- 2018-04-20 WO PCT/KR2018/004642 patent/WO2018194427A1/ko unknown
- 2018-04-20 EP EP18787918.4A patent/EP3479827B1/en active Active
- 2018-04-20 US US16/311,960 patent/US11298314B2/en active Active
- 2018-04-20 ES ES18787918T patent/ES2949946T3/es active Active
- 2018-04-20 CA CA3031678A patent/CA3031678C/en active Active
-
2019
- 2019-04-29 CO CONC2019/0004317A patent/CO2019004317A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101887586B1 (ko) | 2018-08-10 |
| ES2949946T3 (es) | 2023-10-04 |
| US11298314B2 (en) | 2022-04-12 |
| IL266873A (en) | 2019-08-29 |
| CN109862897B (zh) | 2024-01-30 |
| AU2018256263A1 (en) | 2019-05-16 |
| IL266873B2 (en) | 2024-04-01 |
| WO2018194427A8 (ko) | 2019-01-03 |
| EP3479827A4 (en) | 2019-08-07 |
| WO2018194427A1 (ko) | 2018-10-25 |
| JP2020517581A (ja) | 2020-06-18 |
| EP3479827A1 (en) | 2019-05-08 |
| RU2736974C1 (ru) | 2020-11-23 |
| CN109862897A (zh) | 2019-06-07 |
| CA3031678C (en) | 2021-08-31 |
| IL266873B1 (en) | 2023-12-01 |
| CO2019004317A2 (es) | 2019-05-10 |
| BR112019008065A2 (pt) | 2019-07-02 |
| AU2018256263B2 (en) | 2021-05-06 |
| EP3479827B1 (en) | 2023-05-10 |
| JP7034497B2 (ja) | 2022-03-14 |
| CA3031678A1 (en) | 2018-10-25 |
| US20190201328A1 (en) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| MX2019002289A (es) | Composicion inyectable para reduccion de grasa localizada, sin dolor, edema ni efectos secundarios, y metodo para preparar la misma. | |
| EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| MY181928A (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| EA201500050A1 (ru) | Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| Landy | Combined use of clozapine and electroconvulsive therapy | |
| MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2022009736A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
| MX2020005879A (es) | Composiciones administrables vía intravenosa que comprenden ácidos de grado farmacéutico y reguladores del ph, y el uso de las mismas para tratar enfermedades de disfunción mitocondrial, enfermedades metabólicas y de disfunción del modelado de huesos y tejidos. | |
| BR112018008893A8 (pt) | método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica | |
| MX2015017879A (es) | Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MX2009013202A (es) | Derivados terapeuticos de pirazoloquinolina. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| RU2014149700A (ru) | Композиции для доставки активных ингредиентов | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| GS et al. | ESRA19-0663 A new indication of erector spinae plane block for perioperative analgesia is percutaneous nephrolithotomy (PCNL) surgery: case series | |
| EA201992826A1 (ru) | 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ | |
| MD4639B1 (ro) | Modulatori alosterici pozitivi ai receptorului nicotinic acetilcolinic |